Hard-to-Drug Target Programs (e.g., GPCRs)

About Nabla Bio

Nabla Bio is a private, pre-clinical stage biotech leveraging an integrated AI and wet-lab platform to design novel antibodies and multispecific biologics. Its core technology, the JAM generative modeling system, is trained on massive protein data and refined with proprietary human-relevant assays to enable epitope-precise, de novo drug design. The company operates a platform-plus-partnership business model, collaborating with pharmaceutical partners while advancing its own pipeline, and is positioned to tackle historically difficult drug targets like GPCRs and ion channels.

Other Multiple targets Drugs